Genomics and the prospects of existing and emerging therapeutics for cardiovascular diseases

Current Pharmaceutical Design

Volumn 15, Issue 27, 2009, Pages 3193-3206

  Zaiou, M ^a   Benachour, H ^a   Marteau, J B ^a   Visvikis Siest, S ^a   Siest, G ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

Author keywords

Antimicrobial peptides; Biologics; Cardiovascular diseases; Drug target; Pharmacogenomics

Indexed keywords

2 [1 CARBOXY 2 [4 [2 (5 METHYL 2 PHENYL 4 OXAZOLYL)ETHOXY]PHENYL]ETHYLAMINO]BENZOIC ACID METHYL ESTER; ABC TRANSPORTER; ANGIOTENSIN RECEPTOR ANTAGONIST; APELIN RECEPTOR; APOLIPOPROTEIN E; ATORVASTATIN; ATRIAL NATRIURETIC FACTOR ALPHA; BEZAFIBRATE; CIPROFIBRATE; CYTOCHROME P450; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETC 216; FARGLITAZAR; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIPOMERSEN; MURAGLITAZAR; NESIRITIDE; PEPTIDE YY [3-36]; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEXELIZUMAB; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UROCORTIN;

ACUTE HEART INFARCTION; ANTISENSE THERAPY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DRUG TARGETING; DYSLIPIDEMIA; GENOMICS; GENOTYPE; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HEREDITY; HUMAN; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA; LIPID PEROXIDATION; MUSCLE DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PHARMACOGENETICS; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; BIOLOGICAL PRODUCTS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DRUG DESIGN; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENOMICS; HUMANS; PATIENT SELECTION; PEPTIDES; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS;

EID: 70449424142     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209789058011     Document Type: Review

References (150)

1. Zambrowicz BP, Sands AT. Knockouts model the 100 best-selling drugs - will they model the next 100? Nat Rev Drug Discov 2003; 2: 38-51.
2. Clark RW. Raising high-density lipoprotein with cholesteryl ester transfer protein inhibitors. 1: Curr Opin Pharmacol 2006; 6: 162-168
3. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357: 2109-2122 (Pubitemid 350146106)
4. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752
5. Brazhnik P, de la Fuente A, Mendes P. Gene networks: how to put the function in genomics. Trends Biotechnol 2002; 20: 467-472 (Pubitemid 35292359)
6. Siest G, Jeannesson E, Berrahmoune H, Maumus S, Marteau JB, Mohr S. et al. Pharmacogenomics and drug response in cardiovascular disorders. Pharmacogenomics 2004; 5: 779-802. (Pubitemid 39386749)
7. Johnson JA, Cavallari LH. Cardiovascular pharmacogenomics. Exp Physiol 2005; 90: 283-289
8. Segal E, Friedman N, Kaminski N, Regev A, Koller D. From signatures to models: understanding cancer using microarrays. Nat Genet 2005; 37: S38-45. (Pubitemid 40770402)
9. Capdevila JH, Falck JR, Imig JD. Roles of the cytochromes P450 arachidonic acid monooxygenases in the control of systemic blood pressure and experimental hypertension. Kidney Int 2007; 72: 683-689
10. Gambier N, Batt AM, Marie B, Pfister M, Siest G, Visvikis-Siest S. Association of CYP2A6*1B genetic variant with the amount of smoking in French adults from the Stanislas cohort. Pharmacogenomics J 2005; 5: 271-275 (Pubitemid 41131719)
11. Siest G, Jeannesson E, Marteau JB, Samara A, Marie B, Pfister M, et al. Transcription factor and drug-metabolizing enzyme gene expression in lymphocytes from healthy human subjects. Drug Metab Dispos 2008; 36:182-189
12. Bertrand-Thiebault C, Ferrari L, Boutherin-Falson O, Kockx M, Desquand-Billiald S, et al. Cytochromes P450 are differently expressed in normal and varicose human saphenous veins: linkage with varicosis. Clin Exp Pharmacol Physiol 2004; 31: 295-301. (Pubitemid 38803071)
13. Fisslthaler B, Michaelis UR, Randriamboavonjy V, Busse R, Fleming I. Cytochromes P450 epoxygenases and vascular tone: novel role for HMG-CoA reductase inhibitors in the regulation of CYP 2C expression. Biochim Biophys Acta 2003; 1619: 332-339 (Pubitemid 36160611)
14. Matsumoto M, Sata M, Fukuda D, Tanaka K, Soma M, Hirata Y, et al. Orally administered eicosapentaenoic acid reduces and stabilizes atherosclerotic lesions in ApoE-deficient mice. Atherosclerosis 2008; 197: 524-533
15. Spiecker M, Darius H, Hankeln T, Soufi M, Sattler A M, Schaefer JR, et al. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation 2004; 110: 2132-2136 (Pubitemid 39372490)
16. Kim KA, Park PW, Hong SJ, Park JY. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther 2008; 84: 236-242
17. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45: 89-118.
18. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-239 (Pubitemid 38924592)
19. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278
20. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 2002; 106: 1024-1028 (Pubitemid 34925341)
21. Evans M, Rees A. The myotoxicity of statins. Curr Opin Lipidol 2002; 13: 415-420
22. LaRosa JC. Statins and risk of coronary heart disease. JAMA 2000; 283: 2935-2936
23. Schmitz G, Schmitz-Madry A, Ugocsai P. Pharmacogenetics and pharmacogenomics of cholesterol-lowering therapy. Curr Opin Lipidol 2007; 18: 164-173
24. Vermes A, Vermes I. Genetic polymorphisms in cytochrome P450 enzymes: effect on efficacy and tolerability of HMG-CoA reductase inhibitors. Am J Cardiovasc Drugs 2004; 4: 247-255 (Pubitemid 39206618)
25. Mangravite LM, Thorn CF, Krauss RM. Clinical implications of pharmacogenomics of statin treatment. Pharmacogenomics J 2006; 6: 360-374 (Pubitemid 44811531)
26. Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton VP Jr, Ridker PM. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 2004; 29: 2821-2827 (Pubitemid 38747801)
27. Donnelly LA, Doney AS, Dannfald J, Whitley AL, Lang CC, Morris AD, et al. A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study. Pharmacogenet Genomics 2008; 18(12): 1021-1026
28. Krauss RM, Mangravite LM, Smith JD, Medina MW, Wang D, Guo X, et al. Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment. Circulation 2008; 117: 1537-1544
29. Medina MW, Gao F, Ruan W, Rotter JI, Krauss RM. Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin. Circulation 2008; 118: 355-362
30. Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol 2002; 155: 487-495 (Pubitemid 34208040)
31. Wang XL, McCredie RM, Wilcken DE. Polymorphisms of the apolipoprotein E gene and severity of coronary artery disease defined by angiography. Arterioscler Thromb Vasc Biol 1995; 15: 1030-1034
32. Nassar BA, Darvesh S, Bevin LD, Rockwood K, Kirkland SA, O'Neill BJ, et al. Relation between butyrylcholinesterase K variant, paraoxonase 1 (PON1) Q and R and apolipoprotein E epsilon 4 genes in early-onset coronary artery disease. Clin Biochem 2002; 35: 205-209 (Pubitemid 34634182)
33. Lehtinen S, Lehtimäki T, Sisto T, Salenius JP, Nikkilä M, Jokela H, et al. Apolipoprotein E polymorphism, serum lipids, myocardial infarction and severity of angiographically verified coronary artery disease in men and women. Atherosclerosis 1995; 114: 83-91.
34. Wilson PW, Myers RH, Larson MG, Ordovas JM, Wolf PA, Schaefer EJ. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. JAMA 1994; 272: 1666-1671
35. Stengård JH, Zerba KE, Pekkanen J, Ehnholm C, Nissinen A, Sing CF. Apolipoprotein E polymorphism predicts death from coronary heart disease in a longitudinal study of elderly Finnish men. Circulation 1995; 91: 265-269
36. Wilson PW, Schaefer EJ, Larson MG, Ordovas JM. Apolipoprotein E alleles and risk of coronary disease. A meta-analysis. Arterioscler Thromb Vasc Biol 1996; 16: 1250-1255
37. Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, Chen H, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007; 316: 1331-1336 (Pubitemid 46871653)
38. Guangda X, Yuhua W. Apolipoprotein e4 allele and endothelium-dependent arterial dilation in Type 2 diabetes mellitus without angiopathy. Diabetologia 2003; 46: 514-519 (Pubitemid 36577795)
39. Vaisi-Raygani A, Rahimi Z, Nomani H, Tavilani H, Pourmotabbed T. The presence of apolipoprotein epsilon4 and epsilon2 alleles augments the risk of coronary artery disease in type 2 diabetic patients. Clin Biochem 2007; 40: 1150-1156 (Pubitemid 47379326)
40. Eichner JE, Ferrell RE, Kamboh MI, Kuller LH, Becker DJ, Drash AL, et al. The impact of the apolipoprotein E polymorphism on the lipoprotein profile in insulin-dependent diabetes: the Pittsburgh Epidemiology of Diabetes Complications Study IX. Metabolism 1992; 4: 347-351
41. Chowdhury TA, Dyer PH, Kumar S, Gibson SP, Rowe BR, Davies SJ, et al. Association of apolipoprotein epsilon2 allele with diabetic nephropathy in Caucasian subjects with IDDM. Diabetes 1998; 47: 278-280 (Pubitemid 28079987)
42. De Knijff P, Stalenhoef AF, Mol MJ, Gevers Leuven JA, Smit J, Erkelens DW, et al. Influence of apo E polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 1990; 83: 89-97. (Pubitemid 20210749)
43. Nestel P, Simons L, Barter P, Clifton P, Colquhoun D, Hamilton-Craig I, et al. A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin. Atherosclerosis 1997; 129: 231-239 (Pubitemid 27135325)
44. Ordovas JM, Lopez-Miranda J, Perez-Jimenez F, Rodriguez C, Park JS, Cole T, et al. Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy. Atherosclerosis 1995; 113: 157-166
45. Ballantyne CM, Herd JA, Stein EA, Ferlic LL, Dunn JK, Gotto AM Jr, et al. Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy. J Am Coll Cardiol 2000; 36: 1572-1578
46. Pedro-Botet J, Schaefer EJ, Bakker-Arkema RG, Black DM, Stein EM, Corella D, et al. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis 2001; 158: 183-193 (Pubitemid 32735483)
47. Gerdes LU, Gerdes C, Kervinen K, Savolainen M, Klausen IC, Hansen PS, et al. The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction : a substudy of the Scandinavian simvastatin survival study. Circulation 2000; 101:1366-1371 (Pubitemid 30169856)
48. Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ. Nuclear receptors and lipid physiology: opening the X-files. Science 2001; 294: 1866-1870 (Pubitemid 33101573)
49. Beaven SW, Tontonoz P. Nuclear receptors in lipid metabolism: Targeting the heart of dyslipidemia. Annu Rev Med 2006; 57: 313-329 (Pubitemid 43261994)
50. Hanniman EA, Sinal CJ. Nuclear receptors: novel therapeutic targets for the treatment and prevention of atherosclerosis. Drug Discov Today Therapeut Strat 2004; 2: 155-161 (Pubitemid 40197622)
51. Bradley MN, Tontonoz P. Lesion macrophages are a key target for the antiatherogenic effects of LXR agonists. Arterioscler Thromb Vasc Biol 2005; 25: 10-11 (Pubitemid 40054246)
52. Bensinger SJ, Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 2008; 454: 470-477 (Pubitemid 50280209)
53. Rigamonti E, Chinetti-Gbaguidi G, Staels B. Regulation of macrophage functions by PPAR-alpha, PPAR-gamma, and LXRs in mice and men. Arterioscler Thromb Vasc Biol 2008; 28: 1050-1059
54. Heppner TJ, Bonev AD, Eckman DM, Gomez MF, Petkov GV, Nelson MT. Novel PPARgamma agonists GI 262570, GW 7845, GW 1929, and pioglitazone decrease calcium channel function and myogenic tone in rat mesenteric arteries. Pharmacology 2005; 73: 15-22.
55. Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005; 294: 2581-2586 (Pubitemid 41697247)
56. AstraZeneca discontinues development of GALIDATM (tesaglitzar) 2006; [online], http://www.astrazeneca.com/pressrelease/5240.aspx.
57. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Lancet 2006; 368: 1096-1105
58. Cresci S. PPAR genomics and pharmacogenomics: implications for cardiovascular disease. PPAR Res 2008; 2008: 374549. (Pubitemid 351701952)
59. Vohl MC, Lepage P, Gaudet D, Brewer CG, Bétard C, Perron P, et al. Molecular scanning of the human PPARa gene: association of the L162v mutation with hyperapobetalipoproteinemia. J Lipid Res 2000; 41: 945-952 (Pubitemid 30434326)
60. Flavell DM, Jamshidi Y, Hawe E, Pineda Torra I, Taskinen MR, Frick MH, et al. Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease. Circulation 2002; 105: 1440-1445 (Pubitemid 34263275)
61. Shin MJ, Kanaya AM, Krauss RM. Polymorphisms in the peroxisome proliferator activated receptor alpha gene are associated with levels of apolipoprotein CIII and triglyceride in African-Americans but not Caucasians. Atherosclerosis 2008; 198: 313-319
62. Flavell DM, Pineda Torra I, Jamshidi Y, Evans D, Diamond JR, Elkeles RS, et al. Variation in the PPARalpha gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects. Diabetologia 2000; 43: 673-680
63. Tai ES, Demissie S, Cupples LA, Corella D, Wilson PW, Schaefer EJ, et al. Association between the PPARA L162V polymorphism and plasma lipid levels: the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 2002; 22: 805-810 (Pubitemid 34517793)
64. Rhee EJ, Kwon CH, Lee WY, Kim SY, Jung CH, Kim BJ et al. No association of Pro12Ala polymorphism of PPAR-gamma gene with coronary artery disease in Korean subjects. Circ J 2007; 71: 338-342 (Pubitemid 46409535)
65. Bossé Y, Pascot A, Dumont M, Brochu M, Prud'homme D, Bergeron J, et al. Influences of the PPAR alpha-L162V polymorphism on plasma HDL(2)-cholesterol response of abdominally obese men treated with gemfibrozil. Genet Med 2002; 4: 311-315
66. Tai ES, Collins D, Robins SJ, O'Connor JJ Jr, Bloomfield HE, Ordovas JM, et al. The L162V polymorphism at the peroxisome proliferator activated receptor alpha locus modulates the risk of cardiovascular events associated with insulin resistance and diabetes mellitus: the Veterans Affairs HDL Intervention Trial (VA-HIT). Atherosclerosis 2006; 187: 153-160 (Pubitemid 43833359)
67. Robitaille J, Brouillette C, Houde A, Lemieux S, Pérusse L, Tchernof A, et al. Association between the PPARalpha-L162V polymorphism and components of the metabolic syndrome. J Hum Genet 2004; 49: 482-489 (Pubitemid 39314367)
68. Chuang LM, Hsiung CA, Chen YD, Ho LT, Sheu WH, Pei D, et al. Sibling-based association study of the PPARgamma2 Pro12Ala polymorphism and metabolic variables in Chinese and Japanese hypertension families: a SAPPHIRe study. Stanford Asian-Pacific Program in Hypertension and Insulin Resistance. J Mol Med 2001; 79: 656-664 (Pubitemid 33071154)
69. Buzzetti R, Petrone A, Caiazzo AM, Alemanno I, Zavarella S, Capizzi M, et al. PPAR-gamma2 Pro12Ala variant is associated with greater insulin sensitivity in childhood obesity. Pediatr Res 2005; 57: 138-140 (Pubitemid 40039904)
70. Tönjes A, Scholz M, Loeffler M, Stumvoll M. Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma with Pre-diabetic phenotypes: meta-analysis of 57 studies on nondiabetic individuals. Diabetes Care 2006; 29: 2489-2497 (Pubitemid 44912258)
71. Ridker PM, Cook NR, Cheng S, Erlich HA, Lindpaintner K, Plutzky J, et al. Alanine for proline substitution in the peroxisome proliferator-activated receptor gamma-2 (PPARG2) gene and the risk of incident myocardial infarction. Arterioscler Thromb Vasc Biol 2003; 23: 859-863 (Pubitemid 36566178)
72. Pischon T, Pai JK, Manson JE, Hu FB, Rexrode KM, Hunter D, et al. Peroxisome proliferator-activated receptor-gamma2 P12A polymorphism and risk of coronary heart disease in US men and women. Arterioscler Thromb Vasc Biol 2005; 25: 1654-1658 (Pubitemid 41098936)
73. Wolford JK, Yeatts KA, Dhanjal SK, Black MH, Xiang AH, Buchanan TA, et al. Sequence variation in PPARG may underlie differential response to troglitazone. Diabetes 2005; 54: 3319-3325
74. Deeb SS, Fajas L, Nemoto M, Pihlajamäki J, Mykkänen L, Kuusisto J, et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998; 20: 284-287 (Pubitemid 28507675)
75. Tai ES, Corella D, Deurenberg-Yap M, Adiconis X, Chew SK, Tan CE, et al. Differential effects of the C1431T and Pro12Ala PPARgamma gene variants on plasma lipids and diabetes risk in an Asian population. J Lipid Res 2004; 45: 674-685 (Pubitemid 38405674)
76. Kang ES, Park SY, Kim HJ, Kim CS, Ahn CW, Cha BS, et al. Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor gamma2 gene on rosiglitazone response in type 2 diabetes. Clin Pharmacol Ther 2005; 78: 202-208 (Pubitemid 41112288)
77. Hansen L, Ekstrøm CT, Tabanera Y Palacios R, Anant M, Wassermann K, et al. The Pro12Ala variant of the PPARG gene is a risk factor for peroxisome proliferator-activated receptor-gamma/alpha agonist-induced edema in type 2 diabetic patients. J Clin Endocrinol Metab 2006; 91: 3446-3450 (Pubitemid 44402117)
78. Andrulionytè L, Zacharova J, Chiasson JL, Laakso M, STOP-NIDDM Study Group. Common polymorphisms of the PPAR-gamma2 (Pro12Ala) and PGC-1alpha (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial. Diabetologia 2004; 47: 2176-2184 (Pubitemid 40174691)
79. Blüher M, Lübben G, Paschke R. Analysis of the relationship between the Pro12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes. Diabetes Care 2003; 26: 825-831 (Pubitemid 36929350)
80. Snitker S, Watanabe RM, Ani I, Xiang AH, Marroquin A, Ochoa C, et al. Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-gamma2 gene variant: results from the Troglitazone in Prevention of Diabetes (TRIPOD) study. Diabetes Care 2004; 27: 1365-1368 (Pubitemid 38679984)
81. Skogsberg J, McMahon AD, Karpe F, Hamsten A, Packard CJ, Ehrenborg E. Peroxisome proliferator activated receptor delta genotype in relation to cardiovascular risk factors and risk of coronary heart disease in hypercholesterolaemic men. West of Scotland Coronary Prevention Study. J Intern Med 2003; 254: 597-604. (Pubitemid 37521857)
82. Aberle J, Hopfer I, Beil FU, Seedorf U. Association of the T+294C polymorphism in PPAR delta with low HDL cholesterol and coronary heart disease risk in women. Int J Med Sci 2006; 3: 108-111 (Pubitemid 44035233)
83. Phillips MI, Kimura B. Gene therapy for hypertension: antisense inhibition of the renin-angiotensin system. Methods Mol Med 2005; 108: 363-379
84. Vanecková I, Kopkan L, Husková Z, Vanourková Z, Schejbalová S, Cervenka L, et al. AT1 receptor antisense therapy transiently lowers blood pressure in Ren-2 transgenic rats. Vasc Pharmacol 2007; 47: 63-67 (Pubitemid 46818138)
85. Ji R, Cheng Y, Yue J, Yang J, Liu X, Chen H, et al. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation. Circ Res 2007; 100: 1579-1588 (Pubitemid 46897261)
86. Yang B, Lin H, Xiao J, Lu Y, Luo X, Li B, et al. The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med 2007; 13: 486-491 (Pubitemid 46559834)
87. Xiao J, Yang B, Lin H, Lu Y, Luo X, Wang Z. Novel approaches for gene-specific interference via manipulating actions of microRNAs: examination on the pacemaker channel genes HCN2 and HCN4. J Cell Physiol 2007; 212: 285-292 (Pubitemid 47025616)
88. Athyros VG, Kakafika AI, Tziomalos K, Karagiannis A, Mikhailidis DP. Antisense technology for the prevention or the treatment of cardiovascular disease: the next blockbuster? Expert Opin Investig Drugs 2008; 17: 969-972
89. Visser ME, Jakulj L, Kastelein JJ, Stroes ES. LDL-C-lowering therapy: current and future therapeutic targets. Curr Cardiol Rep 2008; 10: 512-520
90. Menschikowski M, Hagelgans A, Siegert G. Secretory phospholipase A2 of group IIA: is it an offensive or a defensive player during atherosclerosis and other inflammatory diseases? Prostaglandins Other Lipid Mediat 2006; 79: 1-33.
91. MacPhee CH, Moores KE, Boyd HF, Dhanak D, Ife RJ, Leach CA et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J 1999; 338: 479-487 (Pubitemid 129512274)
92. Corson MA, Jones PH, Davidson MH. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol 2008; 101: 41F-50F.
93. McConnell JP, Hoefner DM. Lipoprotein-associated phospholipase A2. Clin Lab Med 2006; 26: 679-697
94. Kolodgie FD, Burke AP, Skorija KS, Ladich E, Kutys R, Makuria AT, et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2006; 26: 2523-2529 (Pubitemid 44607475)
95. Wilensky RL, Shi Y, Mohler ER 3rd, Hamamdzic D, Burgert ME, Li J, et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med 2008; 14: 1059-1066
96. Hoffmann MM, Winkler K, Renner W, Winkelmann BR, Seelhorst U, Wellnitz B, et al. Genetic variants and haplotypes of lipoprotein associated phospholipase A2 and their influence on cardiovascular disease (The Ludwigshafen Risk and Cardiovascular Health Study). J Thromb Haemost 2009; 7: 41-48
97. Sutton BS, Crosslin DR, Shah SH, Nelson SC, Bassil A, Hale AB, et al. Comprehensive genetic analysis of the platelet activating factor acetylhydrolase (PLA2G7) gene and cardiovascular disease in case-control and family datasets. Hum Mol Genet 2008; 17:1318-1328 (Pubitemid 351566968)
98. Marteau JB, Gambier N, Jeannesson E, Siest G, Visvikis-Siest S. Pharmacogenomics and antihypertensive drugs: a path toward personalized medicine. Per Med 2007; 4:393-412 (Pubitemid 350303098)
99. Dong B, Zhang C, Feng JB, Zhao YX, Li SY, Yang YP, et al. Overexpression of ACE2 enhances plaque stability in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol 2008; 28:1270-1276
100. Ikejima H, Imanishi T, Tsujioka H, Kuroi A, Kobayashi K, Shiomi M, et al. Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-gamma- modulating activity, on nitric oxide bioavailability and atherosclerotic change. J Hypertens 2008; 26: 964-972
101. Imanishi T, Ikejima H, Tsujioka H, Kuroi A, Kobayashi K, Muragaki Y, et al. Addition of eplerenone to an angiotensin-converting enzyme inhibitor effectively improves nitric oxide bioavailability. Hypertension 2008; 51: 734-741 (Pubitemid 351301528)
102. Sonoda M, Aoyagi T, Takenaka K, Uno K, Nagai R. A one-year study of the antiatherosclerotic effect of the angiotensin-II receptor blocker losartan in hypertensive patients. A comparison with angiotension-converting enzyme inhibitors. Int Heart J 2008; 49:95-103.
103. Hernández Prada JA, Ferreira AJ, Katovich MJ, Shenoy V, Qi Y, Santos RA, et al. Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension 2008; 51:1312-1317 (Pubitemid 351555943)
104. Lula I, Denadai AL, Resende JM, de Sousa FB, de Lima GF, Pilo-Veloso D, et al. Study of angiotensin-(1-7) vasoactive peptide and its beta-cyclodextrin inclusion complexes: complete sequence-specific NMR assignments and structural studies. Peptides 2007; 28: 2199-2210
105. Hall FC, Dalbeth N. Disease modification and cardiovascular risk reduction: two sides of the same coin? Rheumatology (Oxford) 2005; 44: 1473-1482
106. Wolfe F, Freundlich B, Straus WL. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 2003; 30: 36-40. (Pubitemid 36077769)
107. Nishida K, Okada Y, Nawata M, Saito K, Tanaka Y. Induction of yperadiponectinemia following long-term treatment of patients with rheumatoid arthritis with infliximab (IFX), an anti-TNF-alpha antibody. Endocr J 2008; 55: 213-216
108. Mann DL, Bozkurt B, Torre-Amione G, Soran OZ, Sivasubramanian N. Effect of the soluble TNF-antagonist etanercept on tumor necrosis factor bioactivity and stability. Clin Transl Sci 2008; 2: 142-145
109. Sbarsi I, Falcone C, Boiocchi C, Campo I, Zorzetto M, De Silvestri A, et al. Inflammation and atherosclerosis: the role of TNF and TNF receptors polymorphisms in coronary artery disease. Int J Immunopathol Pharmacol 2007; 20:145-154 (Pubitemid 46506886)
110. Ledford H. The future of pharma. Nature (news, published on line 9 October 2008, doi:10.1038/news.2008.1161).
111. Lacaná E, Amur S, Mummanneni P, Zhao H, Frueh FW. The emerging role of pharmacogenomics in biologics. Clin Pharmacol Ther 2007; 82: 466-471
112. Eikelboom JW, O'Donnell M. Pexelizumab does not "complement" percutaneous coronary intervention in patients with ST-elevation myocardial infarction. JAMA 2007; 297: 91-92
113. Patel JA, Ghatak SB. Pexelizumab and its role in the treatment of myocardial infarction and in coronary artery bypass graft surgery: a review. Recent Patents Cardiovasc Drug Discov 2008; 3: 145-152
114. Maisel A, Mueller C, Adams K Jr, Anker SD, Aspromonte N, Cleland JG, et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Failure 2008; 10: 824-839
115. Suwa M, Seino Y, Nomachi Y, Matsuki S, Funahashi K. Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the 'real world' of therapy. Circ J 2005; 69: 283-290
116. Chen HH, Burnett JC Jr. The natriuretic peptides in heart failure: diagnostic and therapeutic potentials. Proc Assoc Am Physicians 1999; 111: 406-416 (Pubitemid 29446883)
117. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al. Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347: 161-167 (Pubitemid 34803684)
118. Summary for patients in: J Fam Pract 2002; 51: 816.
119. Jessup M, Brozena S. Heart failure. N Engl J Med 2003; 348: 2007-2018
120. Lanfear DE.Genetic variation in the natriuretic peptide system and heart failure. Heart Fail Rev 2008; [Epub ahead of print].
121. Vaughan J, Donaldson C, Bittencourt J, Perrin MH, Lewis K, Sutton S, et al. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 1995; 378: 287-292
122. Ng LL, Loke IW, O'Brien RJ, Squire IB, Davies JE. Plasma urocortin in human systolic heart failure. Clin Sci (Lond) 2004; 106: 383-388 (Pubitemid 38553586)
123. Brar BK, Jonassen AK, Egorina EM, Chen A, Negro A, Perrin MH, et al. Urocortin-II and urocortin-III are cardioprotective against ischemia reperfusion injury: an essential endogenous cardioprotective role for corticotropin releasing factor receptor type 2 in the murine heart. Endocrinology 2004; 145: 24-35. (Pubitemid 38094496)
124. García-Villalón AL, Amezquita YM, Monge L, Fernández N, Climent B, Sánchez A, et al. Mechanisms of the protective effects of urocortin on coronary endothelial function during ischemia-reperfusion in rat isolated hearts. Br J Pharmacol 2005; 145: 490-494 (Pubitemid 40966278)
125. Davis ME, Pemberton CJ, Yandle TG, Fisher SF, Lainchbury JG, Frampton CM, et al. Urocortin 2 infusion in human heart failure. Eur Heart J 2007; 28: 2589-2597 (Pubitemid 350071510)
126. Agnello D, Bertini R, Sacco S, Meazza C, Villa P, Ghezzi P. Corticosteroid-independent inhibition of tumor necrosis factor production by the neuropeptide urocortin. Am J Physiol 1998; 275:E757-62. (Pubitemid 28138609)
127. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2000; 52: 11-34. (Pubitemid 30127593)
128. Chun HJ, Ali ZA, Kojima Y, Kundu RK, Sheikh AY, Agrawal R, et al. Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. J Clin Invest 2008; 118: 3343-3354
129. Chandrasekaran B, Dar O, McDonagh T. The role of apelin in cardiovascular function and heart failure. Eur J Heart Fail 2008; 10: 725-732
130. Higazi AA, Lavi E, Bdeir K, Ulrich AM, Jamieson DG, Arder DJ, et al. Defensin stimulates the binding of lipoprotein (a) to human vascular endothelial and smooth muscle cells. Blood 1997; 89: 4290-4298 (Pubitemid 27260236)
131. Barnathan ES, Raghunath PN, Tomaszewski JE, Ganz T, Cines DB, Higazi AA. Immunohistochemical localization of defensin in human coronary vessels. Am J Pathol 1997; 150: 1009-1020 (Pubitemid 27106172)
132. Higazi AA, Nassar T, Ganz T, Rader DJ, Udassin R, Bdeir K, et al. The alpha-defensins stimulate proteoglycan-dependent catabolism of low-density lipoprotein by vascular cells: a new class of inflammatory apolipoprotein and a possible contributor to atherogenesis. Blood 2000; 96: 1393-1398 (Pubitemid 30658469)
133. Chavakis T, Cines DB, Rhee JS, Liang OD, Schubert U, Hammes HP, et al. Regulation of neovascularization by human neutrophil peptides (alpha-defensins): a link between inflammation and angiogenesis. FASEB J 2004; 18: 1306-1308 (Pubitemid 39561585)
134. Higazi AA, Ganz T, Kariko K, Cines DB. Defensin modulates tissue-type plasminogen activator and plasminogen binding to fibrin and endothelial cells. J Biol Chem 1996; 271: 1760-1765 (Pubitemid 26250734)
135. Hooper LV, Stappenbeck TS, Hong CV, Gordon JI. Angiogenins: a new class of microbicidal proteins involved in innate immunity? Nat Immunol 2003; 4: 269-273
136. Kougias P, Chai H, Lin PH, Yao Q, Lumsden AB, Chen C. Neutrophil antimicrobial peptide alpha-defensin causes endothelial dysfunction in porcine coronary arteries. J Vasc Surg 2006; 43: 357-363 (Pubitemid 43221934)
137. Edfeldt K, Agerberth B, Rottenberg ME, Gudmundsson GH, Wang XB, Mandal K, et al. Involvement of the antimicrobial peptide LL-37 in human atherosclerosis. Arterioscler Thromb Vasc Biol 2006; 26: 1551-1557 (Pubitemid 44288982)
138. Li YM, Tan AX, Vlassara H. Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation-modified proteins to a conserved motif. Nat Med 1995; 1: 1057-1061
139. Otvos L Jr, Cudic M, Chua BY, Deliyannis G, Jackson DC. An insect antibacterial peptide-based drug delivery system. Mol Pharm 2004; 1: 220-232
140. Le Y, Yang Y, Cui Y, Yazawa H, Gong W, Qiu C, et al. Receptors for chemotactic formyl peptides as pharmacological targets. Int Immunopharmacol 2002; 2: 1-13. (Pubitemid 33086799)
141. Su SB, Gong W, Gao JL, Shen W, Murphy PM, Oppenheim JJ, et al. A seven-transmembrane, G protein-coupled receptor, FPRL1, mediates the chemotactic activity of serum amyloid A for human phagocytic cells. J Exp Med 1999; 189: 395-402. (Pubitemid 29063260)
142. Le Y, Hu J, Gong W, Shen W, Li B, Dunlop NM, et al. Expression of functional formyl peptide receptors by human astrocytoma cell lines. J Neuroimmunol 2000; 111: 102-108 (Pubitemid 30792066)
143. Le Y, Yazawa H, Gong W, Yu Z, Ferrans VJ, Murphy PM, et al. The neurotoxic prion peptide fragment PrP(106-126) is a chemotactic agonist for the G protein-coupled receptor formyl peptide receptor-like 1. J Immunol 2001; 166: 1448-1451
144. Bhattacharya M, Wang J, Ribeiro FM, Dixon SJ, Feldman RD, Hegele RA, et al. Analysis of a missense variant of the human N-formyl peptide receptor that is associated with agonist-independent beta-arrestin association and indices of inflammation. Pharmacogenomics J 2007; 7:190-199 (Pubitemid 46785160)
145. Benachour H, Zaiou M, Herbeth B, Lambert D, Lamont JL, Pfister M, et al. Human formyl peptide receptor 1 (FPR1) c.32C>T single nucleotide polymorphism is associated with decreased soluble E-selectin levels. In press, Pharmacogenomics 2009.
146. Gaofu Q, Jun L, Xin Y, Wentao L, Jie W, Xiuyun Z, et al. Vaccinating rabbits with a cholesteryl ester transfer protein (CETP) B-Cell epitope carried by heat shock protein-65 (HSP65) for inducing anti-CETP antibodies and reducing aortic lesions in vivo. J Cardiovasc Pharmacol 2005; 45: 591-598 (Pubitemid 40734582)
147. Fredrikson GN, Björkbacka H, Söderberg I, Ljungcrantz I, Nilsson J. Treatment with apo B peptide vaccines inhibits atherosclerosis in human apo B-100 transgenic mice without inducing an increase in peptide-specific antibodies. J Intern Med 2008; 264: 563-570
148. Bansal AT, Barnes MR. Genomics in drug discovery: the best things come to those who wait. Curr Opin Drug Discov Devel 2008; 11(3): 303-311
149. Lanni C, Racchi M, Uberti D, Mazzini G, Stanga S, Sinforiani E, et al. Pharmacogenetics and pharmagenomics, trends in normal and pathological aging studies: focus on p53. Curr Pharm Des 2008; 14(26): 2665-2671
150. Listi F, Caruso M, Incalcaterra E, Hoffmann E, Caimi G, Balistreri CR, et al. Pro-inflammatory gene variants in myocardial infarction and longevity: implications for pharmacogenomics. Curr Pharm Des 2008; 14(26): 2678-2685